sar425899 glucagon glp-1 dual agonist sanofi Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes - Cheang - 2018 How glucagon-like peptide 1 receptor

Current Evidence Gaps No direct head-to-head randomized controlled trials comparing Retatrutide and Cagrilintide monotherapy exist in the published literature

Additionally, the relatively short duration of our study (12 weeks) may not have been sufficient to detect changes in this parameter

A potential drug interaction may mean that two drugs cannot be taken togetheror in some cases, they may be prescribed together at lower doses and with close monitoring

Circulating GH and IGF-I levels are maximal during peripubertal growth and early adulthood

Of note, the tdLN sample from one mouse was lost for the analysis shown in Fig